Asthma is one of the most common chronic disorders in the United States and an emergent disease worldwide. Airway vascular remodeling and increased expression of Vascular endothelial growth factor (VEGF) in lungs and serum of asthmatics correlate with the severity of their disease and the critical role of VEGF in type2 inflammation is also corroborated in animal studies. The mechanism of this contribution is not clear. We have previously shown that VEGF mediates miR-1 downregulation in the lung endothelium and this downregulation is critical for the expression of endothelial adhesion molecules and recruitment of inflammatory cells to the lung. Overexpression of miR-1 in endothelial cells inhibited VEGF mediated proliferation and differentiation. These findings suggested that lung endothelium is the main site of miR-1 regulation and that VEGF, directly and specifically regulates this intrinsic endothelial pathway. We have generated a vascular- specific miR-1 lentiviral vector, and an inducible vascular-specific miR-1 transgenic mouse model to test this endothelial specificity. In preliminary studies delivery of the vascular-specific lentiviral vector inhibited ovalbumin-induced eosinophilia and cytokine release, suggesting that low endothelial miR-1 level is necessary for the propagation of Th2 inflammation. In our preliminary studies on the mechanism of VEGF-mediated miR- 1 downregulation we discovered that VEGF decreases mature miR-1 without lowering its precursors or its binding to Argonaute 2 protein. VEGF stimulation also induced the emergence of unique 3'-adenylated and trimmed miR-1 isoforms (isomiRs) in endothelial cells, suggesting that miR-1 adenylation triggers its degradation. Furthermore, knockdown of a poly(A) polymerase enzymes responsible for miRNA adenylation, increased miR-1 levels and inhibited VEGF-mediated endothelial cell proliferation. Based on our preliminary results we hypothesize that VEGF mediates its effect on airway inflammation through specific adenylation and degradation of miR-1 in the lung endothelial cells.
In aim1 we will characterize the miR-1 isoforms induced by VEGF and Th2 inflammation in the lung and airway endothelium and characterize the kinetics of miR-1 decay and adenylation, the role of miR-1 sequence, and the site of these modification within the endothelial cells.
In aim2 we will test the effect of vascular-specific miR-1 overexpression by lentiviral delivery or transgenic overexpression in VEGF transgenic and Th2 inflammation models and also analyze the effect of poly A polymerase knockdown in these models.
In aim3 we will examine the correlation ofmiR-1 and its adenylation pathway with the severity of type2 inflammation in asthma.

Public Health Relevance

Activation of lung blood vessels by vascular endothelial growth factor (VEGF) is an important component of lung inflammation in asthma and is postulated to play a critical role in determining the severity of this disease. VEGF decreases the level of a small RNA called microRNA-1, and this proposal is focused on understanding the role and regulation of this RNA. We propose to examine the effects of microRNA-1 and its regulation machinery on lung inflammation and analyze the association of this pathway with asthma severity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI125411-01
Application #
9303028
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Togias, Alkis
Project Start
2016-08-01
Project End
2017-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Korde, Asawari; Jin, Lei; Zhang, Jian-Ge et al. (2017) Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. Am J Respir Crit Care Med 196:1443-1455